EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC

Clinical trials for EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC explained in plain language.

Never miss a new study

Get alerted when new EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC trials appear

Sign up with your email to follow new studies for EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for Tough-to-Treat lung cancer: experimental drug challenges standard chemo

Disease control Recruiting now

This study is testing if a new drug called SYS6010 works better and is safer than standard platinum-based chemotherapy for people with advanced non-small cell lung cancer. It is for patients whose cancer has a specific genetic change (EGFR mutation) and has continued to grow desp…

Matched conditions: EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC

Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control

Last updated Mar 16, 2026 15:23 UTC

EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC

Get alerted when new EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC trials appear

New hope for Tough-to-Treat lung cancer: experimental drug challenges standard chemo